Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Letter to Blood| June 1, 2023 Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma Clinical Trials & Observations Armando Santoro, Armando Santoro 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy2IRCCS Humanitas Research Hospital–Humanitas Cancer Center, Rozzano, Milan, Italy https://orcid.org/0000-0003-1709-9492 Search for other works by this author on: This Site PubMed Google Scholar Alison J. Moskowitz, Alison J. Moskowitz 3Memorial Sloan Kettering Cancer Center, New York, NY Search for other works by this author on: This Site PubMed Google Scholar Silvia Ferrari, Silvia Ferrari 4Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy https://orcid.org/0000-0002-9917-2843 Search for other works by this author on: This Site PubMed Google Scholar Carmelo Carlo-Stella, Carmelo Carlo-Stella 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy2IRCCS Humanitas Research Hospital–Humanitas Cancer Center, Rozzano, Milan, Italy Search for other works by this author on: This Site PubMed Google Scholar Julie Lisano, Julie Lisano 5Seagen Inc, Bothell, WA Search for other works by this author on: This Site PubMed Google Scholar Stephen Francis, Stephen Francis 6Bristol Myers Squibb, Princeton, NJ Search for other works by this author on: This Site PubMed Google Scholar Rachael Wen, Rachael Wen 6Bristol Myers Squibb, Princeton, NJ Search for other works by this author on: This Site PubMed Google Scholar Alev Akyol, Alev Akyol 6Bristol Myers Squibb, Princeton, NJ Search for other works by this author on: This Site PubMed Google Scholar Kerry J. Savage Kerry J. Savage 7Centre for Lymphoid Cancer, Division of Medical Oncology, BC Cancer, Vancouver, BC, Canada https://orcid.org/0000-0002-5835-9863 Search for other works by this author on: This Site PubMed Google Scholar Blood (2023) 141 (22): 2780–2783. https://doi.org/10.1182/blood.2022017951 Article history Submitted: August 9, 2022 Accepted: March 1, 2023 First Edition: March 10, 2023 Connected Content A commentary has been published: Targeted therapy in mediastinal gray zone lymphoma Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Request Permissions Cite Icon Cite Search Site Citation Armando Santoro, Alison J. Moskowitz, Silvia Ferrari, Carmelo Carlo-Stella, Julie Lisano, Stephen Francis, Rachael Wen, Alev Akyol, Kerry J. Savage; Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma. Blood 2023; 141 (22): 2780–2783. doi: https://doi.org/10.1182/blood.2022017951 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBlood Search Subjects: Clinical Trials and Observations, Lymphoid Neoplasia TO THE EDITOR: Mediastinal gray zone lymphoma (MGZL) is a rare non-Hodgkin lymphoma occurring predominantly in young men.1 MGZL exhibits pathologic characteristics that are intermediate in nature between those of nodular-sclerosis classical Hodgkin lymphoma (NSCHL) and primary mediastinal large B-cell lymphoma (PMBL), and it is characteristically CD30+.2,3 MGZL tumors, as in NSCHL and PMBL, harbor frequent 9p24.1 copy-number alterations and expression of programmed death-1 (PD-1) ligands 1 and (less commonly) 2.4-7 In a small case series of relapsed/refractory (R/R) MGZL, the PD-1 inhibitor pembrolizumab induced a complete metabolic response in 2 patients.6 Gene expression profiling showed that MGZL clusters between NSCHL and PMBL; whole-exome sequencing supports a common cell of origin.8,9 The 5th-edition update of the World Health Organization and the International Consensus Classification exclude cases arising outside the anterior... References 1.Quintanilla-Martinez L, Fend F. Mediastinal gray zone lymphoma. Haematologica. 2011;96(4):496-499.Google ScholarCrossrefSearch ADS PubMed 2.Eberle FC, Rodriguez-Canales J, Wei L, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96(4):558-566.Google ScholarCrossrefSearch ADS PubMed 3.Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: Do they require a unique therapeutic approach?. Blood. 2015;125(1):33-39.Google ScholarCrossrefSearch ADS PubMed 4.Eberle FC, Salaverria I, Steidl C, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011;24(12):1586-1597.Google ScholarCrossrefSearch ADS PubMed 5.Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.Google ScholarCrossrefSearch ADS PubMed 6.Melani C, Major A, Schowinsky J, et al. PD-1 blockade in mediastinal gray-zone lymphoma. N Engl J Med. 2017;377(1):89-91.Google ScholarCrossrefSearch ADS 7.Sarkozy C, Chong L, Takata K, et al. Gene expression profiling of gray zone lymphoma. Blood Adv. 2020;4(11):2523-2535.Google ScholarCrossrefSearch ADS PubMed 8.Pittaluga S, Nicolae A, Wright GW, et al. Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma. Blood Cancer Discov. 2020;1(2):155-161.Google ScholarCrossrefSearch ADS PubMed 9.Sarkozy C, Hung SS, Chavez EA, et al. Mutational landscape of gray zone lymphoma. Blood. 2021;137(13):1765-1776.Google ScholarCrossrefSearch ADS PubMed 10.Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748.Google ScholarCrossrefSearch ADS PubMed 11.Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229-1253.Google ScholarCrossrefSearch ADS PubMed 12.Evens AM, Kanakry JA, Sehn LH, et al. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol. 2015;90(9):778-783.Google ScholarCrossrefSearch ADS PubMed 13.Wilson WH, Pittaluga S, Nicolae A, et al. A prospective study of mediastinal gray-zone lymphoma. Blood. 2014;124(10):1563-1569.Google ScholarCrossrefSearch ADS PubMed 14.Opdivo (nivolumab). Prescribing information. Bristol Myers Squibb; 2023https://packageinserts.bms.com/pi/pi_opdivo.pdf.15.Adcetris (brentuximab vedotin). Prescribing information. Seagen; 2022https://docs.seagen.com/Adcetris_Full_Ltr_Master.pdf.16.Heiser RA, Grogan BM, Manlove LS, Gardai SJ. CD30+ T regulatory cells, but not CD30+ CD8 T cells, are impaired following brentuximab vedotin treatment in vitro and in vivo. Abstract presented at: American Association for Cancer Research Annual Meeting. 2018. Chicago, USA.17.Cao AT, Law C-L, Gardai SJ, Heiser RA. Brentuximab vedotin-driven immunogenic cell death enhances antitumor immune responses, and is potentiated by PD1 inhibition in vivo. Abstract presented at: American Association for Cancer Research Annual Meeting. 2017. Washington, DC, USA.18.Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183-1194.Google ScholarCrossrefSearch ADS PubMed 19.Gardai SJ, Epp A, Law C-L. Brentuximab vedotin-mediated immunogenic cell death. Cancer Res. 2015;75(suppl 15):2469. Abstract 2469.Google Scholar 20.Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138(6):427-438.Google ScholarCrossrefSearch ADS PubMed 21.Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study. J Clin Oncol. 2019;37(33):3081-3089.Google ScholarCrossrefSearch ADS 22.Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017;129(16):2328-2330.Google ScholarCrossrefSearch ADS PubMed © 2023 by The American Society of Hematology2023 © 2023 by The American Society of Hematology2023 You do not currently have access to this content. Sign in via your Institution

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.